TRUE Private Wealth Advisors’s CRISPR Therapeutics CRSP Stock Holding History

TRUE Private Wealth Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-100	Closed	-$15K	–	325
2020 Q4	$15K	Buy	+100	New	+$11.8K	﹤0.01%	488
2020 Q1	–	Sell	-48	Closed	-$2K	–	700
2019 Q4	$2K	Buy	+48	New	+$2.62K	﹤0.01%	739
2019 Q3	–	Sell	-48	Closed	-$2K	–	321
2019 Q2	$2K	Buy	+48	New	+$1.92K	﹤0.01%	709
2018 Q4	–	Sell	-2,748	Closed	-$122K	–	378
2018 Q3	$122K	Buy	+2,748	New	+$144K	0.02%	323

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

TRUE Private Wealth Advisors's CRSP Position: Q1 2021 in Review

TRUE Private Wealth Advisors sold out of CRISPR Therapeutics (CRSP) in Q1 2021, closing a stake of 100 shares — an estimated $15K sold.

TRUE Private Wealth Advisors first reported a position in CRSP in Q3 2018 and held it in 4 quarters. The position peaked at $122K in Q3 2018. 443 funds tracked by Wall St. Rank hold CRSP as of Q1 2021.

TRUE Private Wealth Advisors reported no remaining CRISPR Therapeutics position as of Q1 2021 after selling out during the quarter.
TRUE Private Wealth Advisors sold 100 CRISPR Therapeutics shares in Q1 2021, an estimated $15K.
TRUE Private Wealth Advisors first reported a position in CRISPR Therapeutics in Q3 2018 and held it in 4 quarters.
TRUE Private Wealth Advisors's CRISPR Therapeutics position peaked at $122K in Q3 2018.
443 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2021.

Based on TRUE Private Wealth Advisors's 13F filing for Q1 2021, filed 12 May 2021.